Working… Menu

The Role of Microparticles as a Biomarker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02626663
Recruitment Status : Withdrawn (PI left the University, sponsor pulled funding)
First Posted : December 10, 2015
Last Update Posted : February 19, 2019
Information provided by (Responsible Party):
Majed Refaai, University of Rochester

Brief Summary:
The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Condition or disease
Atypical Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura Microparticles Microangiopathic Hemolytic Anemia

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
Study Start Date : July 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2022

atypical Hemolytic Uremic Syndrome
Thrombotic thrombocytopenic purpura
other microangiopathic hemolytic anemias

Primary Outcome Measures :
  1. Microparticle/Nanoparticle number (an absolute number) [ Time Frame: an average of 3 months ]
  2. Microparticle/Nanoparticle size (in nanometers or micrometers) [ Time Frame: an average of 3 months ]
  3. Microparticle/Nanoparticle identity (identity of cell type from which they are derived) [ Time Frame: an average of 3 months ]

Secondary Outcome Measures :
  1. Morbidities [ Time Frame: 3 months ]
  2. Mortality [ Time Frame: 3 months ]

Biospecimen Retention:   Samples With DNA
platelet poor plasma samples will be retained. These samples will contain Microparticles and nanoparticles as well as microRNA.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting with Microangiopathic Hemolytic Anemias (MAHA), TTP, and/or aHUS are eligible.

Inclusion Criteria:

  • Patients with MAHA, TTP, and/or aHUS

Exclusion Criteria:

  • Prisoners

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02626663

Layout table for location information
United States, New York
University of Rochester Medical Center
Rochester, New York, United States
Sponsors and Collaborators
University of Rochester
Layout table for investigator information
Principal Investigator: Amy Schmidt, MD PhD University of Rochester

Layout table for additonal information
Responsible Party: Majed Refaai, Associate Professor, University of Rochester Identifier: NCT02626663     History of Changes
Other Study ID Numbers: RSRB00059370
First Posted: December 10, 2015    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemolytic-Uremic Syndrome
Atypical Hemolytic Uremic Syndrome
Purpura, Thrombocytopenic
Anemia, Hemolytic
Purpura, Thrombotic Thrombocytopenic
Pathologic Processes
Blood Coagulation Disorders
Hematologic Diseases
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Kidney Diseases
Urologic Diseases